Scott Gottlieb
Scott Gottlieb, M.D. (b. 1972)
"Special Partner, New Enterprise Associations, Inc.’s healthcare investment team and Resident Fellow of the American Enterprise Institute. Dr. Gottlieb served as the 23rd Commissioner of the U.S. Food and Drug Administration(FDA) from 2017 to 2019. Prior to serving as Commissioner, Dr. Gottlieb held several roles in the public and private sectors including serving as Managing Director, T.R. Winston & Company from 2013 to 2017.
"Dr. Gottlieb was previously the FDA’s Deputy Commissioner for Medical and Scientific Affairs from 2005 to 2007, as well as the senior advisor to the FDA Commissioner from 2003 to 2004. He had been a senior advisor to the Administrator of the Centers for Medicare and Medicaid Services in 2004. Dr. Gottlieb is a member of the National Academy of Medicine and is a Contributor at CNBC. Pfizer Director since 2019." [1]
Gottlieb earned a B.A. in economics form Wesleyan University in 1994 and an M.D. from Mt. Siani School of Medicine in 1999, and has worked in finance and as an adviser on medicine and health policy.
He served in 2004 as an adviser to FDA commissioner Mark McClellan and followed him to the Centers for Medicare and Medicaid Services before joining the AEI. Gottlieb was appointed as the Deputy Commissioner for Medical and Scientific Affairs, the #2 position at the FDA, on July 29, 2005.[2]
Gottlieb's appointment to such a position in the FDA was criticized in media reports which quoted commentators concerned about his lack of experience and possible conflicts of interest.[3] Gottlieb resigned from the FDA in January 2007 to return to the American Enterprise Institute. [4]
In May 2007, an editorial by Gottlieb in the Wall Street Journal titled "Journalist Malpractice" criticized the publishers of the New England Journal of Medicine for publishing drug safety study results on Avandia at a time intended to make the FDA look impotent.[5]
Dr. Gottlieb has also written for the Gilder Biotech Report, the Forbes-Gottlieb Medical Technology Report, the British Medical Journal, and Forbes.com.
References
- ↑ Pfizer Board, March 9, 2020.
- ↑ Alicia Mundy (2005-08-25). Wall Street biotech insider gets No. 2 job at the FDA. Seattle Times.
- ↑ Diana Pearson (2005-09-05). Cronyism in the Bush Administration. Time (magazine).
- ↑ Joshua Slatko (February 2007). "Top official leaves FDA", Med Ad News.
- ↑ Evelyn Pringle (2007-08-15). Protection Racket? The FDA and Avandia. counterpunch.org.
